Please ensure Javascript is enabled for purposes of website accessibility

Here's Why MiMedx Group Inc. Is Crashing Again

By Brian Feroldi - Updated Feb 26, 2018 at 12:34PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The bloodbath continues as the company grapples with news of another investigation.

What happened

Shares of MiMedx Group (MDXG 2.88%), a regenerative medicine company, dropped as much as 22% in early morning trading on Monday. As of 11:10 a.m. EST, the stock was down 13%. The fall is tied to a news report today that the company is under investigation by the U.S. Department of Justice.

So what

Bloomberg reported on Monday morning that federal authorities are looking into MiMedx's government sales practices. According to sources familiar with the matter, MiMedx has allegedly been overcharging the government for its tissue-repair products. What's more, the article claims that the Justice Department is also investigating MiMedx's distribution practices for evidence of inappropriately booking sales of products that hadn't been ordered.

MiMedx responded that it was not aware of any investigation by the Justice Department and that it had previously disclosed its cooperation with a Securities and Exchange Commission investigation into its revenue recognition practices. The company has denied all wrongdoing.

Either way, traders are not taking this news lightly and are selling off shares hard in response.

A graph in descending order, with an arrow pointing down, on a green chalkboard as a man in front of it clutching his head

Image source: Getty Images.

Now what

The last week has been absolutely dreadful for MiMedx Group's shareholders. Shares were slammed on Feb. 20 after the company said that it was delaying its earnings release date in order to conduct an internal accounting investigation. Three days later, the stock was hit again after The Wall Street Journal revealed the company had failed to comply with the Physician Payments Sunshine Act. Including today's plunge, shares have been more than halved in just the last week.

MDXG Chart

MDXG data by YCharts.

It remains unclear whether the company has done anything improper so it is impossible to determine if today's tumble represents a buying opportunity. Given the huge uncertainty, I still think the smart move is to monitor this story from a safe distance.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MiMedx Group, Inc. Stock Quote
MiMedx Group, Inc.
MDXG
$3.57 (2.88%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.